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Summary
 
Mice with a null mutation of the gene encoding interferon consensus sequence-binding pro-
tein (ICSBP) develop a chronic myelogenous leukemia-like syndrome and mount impaired re-
sponses to certain viral and bacterial infections. To gain a mechanistic understanding of the
contributions of ICSBP to humoral and cellular immunity, we characterized the responses of
control and ICSBP
 
2
 
/
 
2
 
 mice to infection with influenza A (flu) and 
 
Leishmania major
 
 (
 
L. major
 
).
Mice of both genotypes survived infections with flu, but differed markedly in the isotype distri-
bution of antiflu antibodies. In sera of normal mice, immunoglobulin (Ig)G2a antibodies were
dominant over IgG1 antibodies, a pattern indicative of a T helper cell type 1 (Th1)-driven re-
sponse. In sera of ICSBP
 
2
 
/
 
2
 
 mice, however, IgG1 antibodies dominated over IgG2a antibod-
ies, a pattern indicative of a Th2-driven response. The dominance of IgG1 and IgE over IgG2a
was detected in the sera of uninfected mice as well. A seeming Th2 bias of ICSBP-deficient
mice was also uncovered in their inability to control infection with 
 
L. major
 
, where resistance is
known to be dependent on IL-12 and IFN-
 
g
 
 as components of a Th1 response. Infected
ICSBP-deficient mice developed fulminant, disseminated leishmaniasis as a result of failure to
mount a Th1-mediated curative response, although T cells remained capable of secreting IFN-
 
g
 
and macrophages of producing nitric oxide. Compromised Th1 differentiation in ICSBP
 
2
 
/
 
2
 
mice could not be attributed to hyporesponsiveness of CD4
 
1
 
 T cells to interleukin (IL)-12;
however, the ability of uninfected and infected ICSBP-deficient mice to produce IL-12 was
markedly impaired. This indicates that ICSBP is a deciding factor in Th responses governing
humoral and cellular immunity through its role in regulating IL-12 expression.
 
T
 
he IFN system is a vital part of innate and adaptive im-
munity. IFN signaling involves a variety of 
 
trans
 
- and
 
cis
 
-acting factors and is mediated through DNA motifs,
designated the IFN-stimulated response element (ISRE)
and the IFN-
 
g
 
–activated sequence, found in promoters of
IFN-inducible genes. These genes play prominent roles in
the control of growth, differentiation, and activation of
cells of the immune system (1–5).
The interferon consensus sequence-binding protein (ICSBP)
belongs to the IFN regulatory factor (IRF) family of tran-
scription factors that have in common the ability to bind to
ISRE. ICSBP is constitutively expressed in the nuclei of
many hematopoietic cells (6–8). The tyrosine-phosphory-
lated form of ICSBP does not bind to DNA independently
(9), but does bind when complexed with other members of
the IRF (IRF-1 and IRF-2) or Ets (PU.1) families as well
as with other elements of transcriptional machinery (10–
13). Since the discovery of ICSBP, most attempts to estab-
lish its exact role in hematopoiesis, immunity, and IFN sig-
naling were constrained to experiments with cell lines and led
to the designation of ICSBP as a transcriptional repressor
(14–16). Recent studies indicated a more complex role in
 
1
 
Abbreviations used in this paper:
 
 CD40L, CD40 ligand; DLN, LN draining
the site of infection; flu, influenza A; ICSBP, interferon consensus se-
quence-binding protein; IRF, IFN regulatory factor; ISRE, IFN-stimu-
lated response element; NO, nitric oxide; ODN, oligodeoxynucleotide;
RT, reverse transcriptase; SLA, soluble leishmanial antigen.
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both immunity and cell cycle regulation (17–19). The first
insights into the in vivo role of ICSBP came from analysis
of recently generated ICSBP knockout mice (ICSBP
 
2
 
/
 
2
 
).
These mice develop a chronic myelogenous leukemia–like
syndrome, but also exhibit impaired resistance to infections
with vaccinia virus, lymphocytic choriomeningitis virus, and
 
Listeria
 
, but not vesicular stomatitis virus (20, 21). Although
it was suggested that enhanced susceptibility to selected in-
fections may be linked to reduced expression of IFN-
 
g
 
, the
exact mechanisms have remained elusive. Of note, in-
creased susceptibility to infections is one of the major
causes of death in patients with myeloid leukemias (22–24).
The basis for impaired immunity in these conditions is un-
certain, and there is currently no effective treatment.
To further understand the role of ICSBP in immunity to
infections, we studied the responses of ICSBP mutant mice
to exposure to influenza A (flu) as a model for antibody-
dependent immune responses and 
 
Leishmania major
 
 as a
model for innate and adaptive immunity. ICSBP
 
2
 
/
 
2
 
 mice
were resistant to flu, but were highly sensitive to infection
with 
 
L. major.
 
 An analysis of changes in the immune system
of ICSBP-deficient mice revealed a failure to develop Th-
1–driven immune responses, which correlated with a defect
in IL-12 production by cells of myeloid origin.
 
Materials and Methods
 
Mice.
 
ICSBP mutant mice were generated as described (21).
Homozygous mutant (
 
2
 
/
 
2
 
), heterozygous (
 
1
 
/
 
2
 
), and wild-
type mice (
 
1
 
/
 
1
 
) on a (C57BL/6 
 
3
 
 129/Sv) F
 
2
 
 background
were bred and maintained under specific pathogen-free condi-
tions.
 
Cell Cultures.
 
Single-cell suspensions were prepared from
spleen, lymph nodes, bone marrow, or whole blood lysed with
ammonium chloride lysing buffer and resuspended in complete
1640 medium: 10% fetal calf serum, 1.5 mM 
 
l
 
-glutamine, 100
U/ml penicillin/streptomycin, nonessential amino acids (GIBCO
BRL, Gaithersburg, MD, or Biofluids, Inc., Rockville, MD), and
50 
 
m
 
M 2-mercaptoethanol. Peritoneal washout cells were har-
vested from untreated mice or mice injected 5 d previously with
thioglycollate medium. To obtain macrophage-enriched popula-
tions, cell suspensions were subjected to 2–4 h of adherence on
plastic and nonadherent cells removed before further use. For in
vitro studies, cells were routinely incubated as 200 
 
m
 
l triplicate al-
iquots in 96-well plates at 37
 
8
 
C in 5% CO
 
2
 
 in air.
 
In Vitro Cell Treatments.
 
The panel of in vitro stimuli used in-
cluded 
 
Escherichia coli
 
 LPS (Sigma Chemical Co., St. Louis, MO),
 
E. coli
 
 DNA (Sigma Chemical Co.), murine recombinant IFN-
 
g
 
(Genzyme, Cambridge, MA), IL-2 and IL-4 (Biosource Int., Ca-
marillo, CA), IL-12 (a gift from Dr. S. Wolf, Genetics Institute,
Cambridge, MA), Con A (Sigma Chemical Co.), and soluble
leishmanial antigens (SLAs) prepared from freeze-thawed 
 
L. major
 
as described (25) at concentrations indicated in the text or in the
legends to the figures. CD40 ligand (CD40L) in the form of
plasma membrane vesicles prepared from Sf9 insect cells infected
with baculovirus recombinant for full-length mouse CD40L was
a gift from Dr. M. Kehry (Boehringer Ingelheim, Ridgefield,
CT). Oligodeoxynucleotides (ODNs) were synthesized, purified,
and used as described (26, 27). Anti–mouse IL-4 and anti–IFN-
 
g
 
mAb were purchased from PharMingen (San Diego, CA).
 
T Helper Differentiation.
 
We used an in vitro assay (28) to as-
sess Th differentiation. CD4
 
1
 
 T cells were purified from pooled
lymph nodes of wild-type or knockout mice and incubated with
mAb to B220 and FcR
 
g
 
 before two rounds of panning on goat
anti–rat Ig-coated plates followed by positive FACS
 
Ò
 
 (Becton
Dickinson, Mountain View, CA) selection. The purity of sorted
CD4
 
1
 
 T cells was 97–99%. To initiate Th development, 10
 
6
 
/ml
cells were plated onto 24-well plates coated with anti-TCR mAb
(H57-597; 3 
 
m
 
g/ml). IL-2 at 50 U/ml was added to all duplicate
cultures. Addition of 1 ng/ml IL-12 and 10 
 
m
 
g/ml anti–IL-4
served to provide Th1-promoting conditions; 1,000 U/ml IL-4
and 10 
 
m
 
g/ml of anti–IFN-
 
g
 
 provided Th2-promoting conditions.
After 5 d of incubation, cells were washed and restimulated with
immobilized anti-TCR mAb in the presence of IL-2 for 24 h.
The concentration of IL-4 and IFN-
 
g
 
 in supernatants was then
determined by ELISA.
 
Reverse Transcriptase PCR Analysis.
 
Total RNA was prepared
from individually frozen tissues or single-cell suspensions using
RNAzol B (Tel-Test, Inc., Friendswood, TX) according to the man-
ufacturer’s instructions. The sequences for primers and probes, as well
as reverse transcriptase (RT)-PCR protocols, were as described
previously (29–33) and as given below for myeloperoxidase (MPO):
probe GGGGTGTACGGCAGCGAGGA; 
 
c-fms
 
: probe CCAGCT-
GCCCATTGGACCATT; CD40L: 5
 
9
 
-GTCTGTTCACTTGGG-
CGGAG-3
 
9
 
; 3
 
9
 
-TTATTCCAGCTCTATGTGCCTTG-5
 
9
 
; probe
CCTGCCCTGTGTTGAACTGCC; IFN-
 
a
 
1: 5
 
9
 
-TGTCTG-
ATGCAGCAGGTGG-3
 
9
 
; 3
 
9
 
-AAGACAGGGCTCTCCAGAC-5
 
9
 
;
probe: CAGGAATTTCCCCTGACC; IFN-
 
b
 
: 5
 
9
 
-CCATCC-
AAGAGATGCTCCAG-3
 
9
 
; 3
 
9
 
-GTGGAGAGCAGTTGA-
GGACA-5
 
9
 
; probe: GTACGTCTCCTGGATGAACT. Enhanced
chemiluminescence reagents (Amersham Life Science Division, Ar-
lington Heights, IL) were used for visualization of the RNA tran-
scripts after electrophoresis of the samples and Southern blot hy-
bridization. Hypoxanthine phosphoribosyltransferase (HPRT RNA)
expression was used as a reference for equalization of cDNA input
for PCR.
 
ELISA.
 
ELISAs were used to determine cytokine and im-
munoglobulin concentrations in biological fluids. Amounts of IL-4
and IFN-
 
g
 
 in the supernatants from cultured cells were deter-
mined using reagents and protocols from PharMingen. mAbs for
IL-12p40 protein detection were purified from C15.1 and C15.6
hybridomas (a gift from Dr. G. Trinchieri, The Wistar Institute,
Philadelphia, PA). Serum Igs of different isotypes, excluding IgG2a,
were determined using pairs of corresponding capture and perox-
idase-conjugated detecting antibodies from SBA, Inc. (Birming-
ham, AL). IgG2a reagents were obtained from PharMingen.
 
ELISpot Assay.
 
Modification of an ELISA method was used
to determine frequencies of IL-12–producing cells in the spleen
and lymph nodes of mice (26, 34). Serial dilutions of single-cell
suspensions were incubated on 96-well microtiter plates coated
with anti–IL-12 mAb (17.8; a gift from Dr. G. Trinchieri). After
4–6 h of incubation, plates were overlaid with a secondary bioti-
nylated anticytokine antibody, washed, and treated with avidin-
conjugated alkaline phosphatase (Vector Laboratories, Inc., Burl-
ingame, CA). Individual producers were visualized and quantitated.
 
Virus Experiments.
 
Live flu A/Philippines/2/82/X-79 (H3N2
type) virus was administered intranasally to mice anesthetized
with methoxyflurane. Sublethal doses for immunization had been
determined previously by in vivo titration in normal mice. 3
wk after primary infection with 10
 
2
 
 tissue culture infectious dose
50% (TCID
 
50
 
) U/mouse, animals were bled from the tail. Sera
were analyzed for the presence of flu-specific antibodies by ELISA
as described elsewhere (35). In brief, sera were titrated on plates 
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coated with formalin-inactivated flu vaccine and specific antibody
isotypes were visualized with alkaline phosphatase-conjugated anti-
IgG2a or anti-IgG1 reagents (Southern Biotechnology Associates,
Inc., Birmingham, AL) to specify Ig isotype. Statistical analysis is
described in the footnote to Table 1.
 
L. major Experiments. L.  major
 
 (WHOM/IL/80/Friedlin) was
provided by Dr. D. Sacks (National Institute of Allergy and Infec-
tious Diseases, National Institutes of Health). Stationary phase pro-
mastigotes (10
 
6
 
) in 50 
 
m
 
l of PBS were injected into the right hind
footpads of mice. Disease progression was monitored by appear-
ance of the infected footpads and frequent measurements of their
thickness with a metric caliper (Fisher Scientific, Pittsburgh, PA).
At defined time points, groups of mice were killed, and parasite
growth and dissemination were determined by limiting-dilution as-
say (25, 33, 36, 37). In brief, serial dilutions of macerated organs
or single-cell suspensions in complete M199 medium were plated
onto 96-well plates containing an underlay of NNN blood agar
(for assays done at 6 and 19 d after infection) or 30% fetal calf
serum in M199 medium (for assays done at 49 and 53 d after in-
fection). After 14 d of incubation at 28
 
8
 
C, the plates were micro-
scopically inspected, and the parasite burden was scored as the
titer of the last positive (parasite-containing) well.
For histopathologic analysis, spleens, livers, lymph nodes drain-
ing the site of infection (DLNs), and footpads from infected mice
were fixed, sectioned, and stained with hematoxylin and eosin. For
RNA expression analysis, DLNs were snap frozen into RNAzol
and kept at 
 
2
 
70
 
8
 
C until further RT-PCR processing, as specified
above. Analysis of cytokine responses and nitric oxide (NO) pro-
duction by spleen and DLN cells after 7 wk of infection was per-
formed by stimulating serially diluted 8 
 
3
 
 10
 
6
 
 cells/ml with 5
 
m
 
g/ml Con A or 25 
 
m
 
g/ml SLA. An ELISA was used for deter-
mination of IL-4 or IFN-
 
g
 
 content in supernatants harvested after
24 or 72 h of incubation. Production of NO was assesed by mea-
surement of NaNO
 
2
 
 concentration using Greiss reagent.
 
Results
 
Responses to Infection with Flu Virus.
 
Although previous
studies showed ICSBP to be crucial for survival after chal-
lenge with lymphocytic choriomeningitis virus and 
 
Listeria
 
(20, 21), the signaling pathways and effector mechanisms
mediating normal resistance are incompletely known. The
present studies were therefore designed to generate a deeper
understanding of the relative role of ICSBP in humoral and
cellular immunity. Resistance of mice to infection with flu
involves secretion of antiviral antibodies, providing an op-
portunity to evaluate Th-dependent antibody responses in
ICSBP
 
2
 
/
 
2
 
 mice. Infection with 
 
L. major
 
 was chosen for an-
alyzing aspects of innate and cellular immunity.
We first examined the responses of ICSBP
 
1
 
/
 
1
 
, ICSBP
 
1
 
/
 
2
 
,
and ICSBP2/2 mice to infection with flu using infectious
virus at priming doses chosen as sublethal in normal mice.
Mice of all three genotypes handled the infection without
significant morbidity and no mortality. When challenged 8 wk
later with a higher virus dose (104 TCID50) that is lethal to
unimmunized mice, they survived as well.
Analysis of Ig isotypes for titers of anti flu serum antibod-
ies revealed striking differences among the three groups of
mice (Table 1). The IgG2a responses of 1/1 mice were
much higher than the IgG1 responses, whereas the oppo-
site was true for the responses of 2/2 mice. The IgG2a
and IgG1 responses of 1/2 mice fell between those of the
1/1 and 2/2 mice, indicative of a gene dosage effect.
It is well established that Ths play a prominent role in
regulating Ig isotype switching in response to T cell–depen-
dent antigens. Th1s expressing IFN-g strongly promote
class switching to IgG2a and IgG3, whereas Th2s produc-
ing IL-4 strongly bias switching toward IgG1 and IgE (38).
The isotype distributions of antiflu antibodies thus suggest a
Th1-driven response by 1/1 mice and a Th2-driven re-
sponse by ICSBP-deficient mice. To determine whether
similar biases were evident in the responses of these mice to
environmental antigens, we examined the distribution of Ig
isotypes in sera of uninfected wild-type and knockout mice
(Fig. 1 A). The observations that the levels of IgG1 and IgE
were markedly higher and the levels of IgG2a reduced in
the sera of 2/2 mice compared with that of +/+ mice
were consistent with the hypothesis of Th2 dominance in
ICSBP2/2 mice.
To determine if the patterns of cytokines expressed by
uninfected ICSBP2/2 mice would show a bias toward a
Table 1. Titers of Virus-specific IgG1 and IgG2a Antibodies in the Sera of ICSBP Mutant Mice Infected with Flu*
ICSBP genotype IgG1 IgG2a Ratio IgG1/IgG2a
1/1 54 (28–104) 1280 (1280–1280) 0.04
1/2 218 (88–526) 98 (32–296) 2.22
2/2 2827 (2136–3740) 20 (10–39) 141.35
Pairwise comparisons‡
1/1 vs. 2/2 P ,0.05 P ,0.05 –
1/2 vs. 2/2 P ,0.05 P .0.05 –
1/1 vs. 1/2 P .0.05 P ,0.05 –
*The numbers in the table are geometric means for sera from seven infected mice/group tested individually. Statistical analysis was performed by one
way analysis of variance. The titers of virus-specific IgG1 and IgG2a in the serum of uninfected mice were all ,20.
‡The significance of difference for IgG1 was P 5 0.002 and for IgG2a was P 5 0.004, based on comparison of three groups.1538 ICSBP Regulation of IL-12 Expression
Th2 profile, we compared the levels of cytokine transcripts
in spleens of wild-type and knockout mice (Fig. 1 B).
Transcripts for the Th2 cytokines (IL-4 and IL-5) were un-
changed; transcripts for IL-10 and the Th1 cytokines (IL-2,
IFN-g) were slightly reduced in the spleens of ICSBP2/2
mice. In contrast, IL-12p40 transcripts, as we reported pre-
viously (21), were markedly reduced in the knockout mice.
Since IL-12 is required for differentiation of Th1 from Th0
cells, these findings suggest that in ICSBP2/2 mice, Th2
cells may develop in a default pathway that exists in the
knockout mice due to chronically impaired IL-12 expres-
sion. Alternatively, Th cells from ICSBP2/2 mice may be un-
able to respond to stimuli that normally drive Th1 responses.
CD41 T Cells from ICSBP2/2 Mice Are Able to Differenti-
ate into Th1s and Th2s. To evaluate the capacity of CD41
T cells from ICSBP2/2 mice to differentiate, we stimulated
purified CD41 T cells with immobilized anti–TCR-a/b
mAb under conditions conducive to polarized differentia-
tion to Th1s or Th2s. Parallel cultures were activated with
medium containing IL-12 and anti–IL-4 mAb to drive Th1
differentiation or IL-4 and anti–IFN-g mAb to drive Th2
differentiation. After 5 d, the cells were washed and restim-
ulated with anti–TCR-a/b and IL-2.
Analyses of cytokines in the supernatants of these cul-
tures showed that CD41 T cells from wild-type or homo-
zygous mutant mice generated highly polarized responses to
either regimen (Table 2). In relation to production by cells
of knockout mice, CD41 T cells from ICSBP1/1 mice
made more IFN-g under Th1 conditions and less IL-4 under
Th2 conditions. These results demonstrated that ICSBP-
deficient CD41 T cells were capable of responding to dif-
ferentiative effects of exogenous IL-12 and IL-4. Respon-
siveness to Th1-inductive stimuli was well maintained in
ICSBP2/2 mice; this suggested that decreased expression of
Th1 cytokines in these animals and the Th2-like pattern of
Ig isotype distribution were due to a deficiency of Th1-
promoting signals. The demonstration that IL-12 is a key
inducer of Th1 differentiation (39, 40) prompted us to ex-
amine the characteristics of IL-12 expression in ICSBP2/2
mice.
IL-12 Secretion Is Impaired in ICSBP2/2 Mice. Although
transcripts of IL-12p35 were comparable in ICSBP2/2 and
ICSBP1/1 mice, transcripts for IL-12p40 were markedly
lower in ICSBP-deficient mice (Fig. 1 B; reference 21). IL-
12p35 expression is constitutive in many cell types, whereas
IL-12p40 is produced after activation of monocytes, mac-
rophages, neutrophils, dendritic cells, and B cells by various
stimuli (for review see reference 41). In the first set of ex-
periments, we examined the ability of cells from spleen,
peritoneum, or bone marrow, either unseparated or en-
riched by adherence for macrophages, to secrete IL-12.
The cultures were treated with IFN-g and either LPS or
CD40L (Fig. 2 A). Cells from wild-type mice produced
consistently higher levels of IL-12p40 than did cells from
ICSBP-deficient mice, with the responses from the latter
often being at or below the limits of detection.
The combinations of IFN-g with LPS or CD40L are very
effective at stimulating IL-12 production by macrophages,
granulocytes, and dendritic cells (42–46). Recent studies,
however, demonstrated the greater effectiveness of unmeth-
ylated CpG motifs present in bacterial DNA at stimulating
B cells to produce IL-12 (26). In a second set of experi-
ments, we used an ELISpot assay to determine the frequen-
cies of lymph node and spleen cells producing IL-12 after
stimulation with synthetic CpG-containing ODNs or bac-
terial DNA from E. coli (Fig. 2 B). Although ODNs and E.
coli DNA induced IL-12 production in mice of either gen-
otype with ODNs being more potent, the proportion of
ICSBP2/2 spleen cells that could be triggered to secrete
IL-12 was much lower than that from wild-type spleen cells;
however, the fold increase in the number of IL-12–secret-
Figure 1. Distribution of serum Ig isotypes with the pattern of consti-
tutive cytokine expression by spleen cells of ICSBP2/2 mice. (A) Con-
centration of Ig isotypes in serum of intact ICSBP2/2 (KO) and ICSBP1/1
(WT) mice as determined by ELISA. (B) RT-PCR analysis of cytokine
RNA expression in spleen of intact KO and WT mice. The mean 6
SEM for each group of mice is shown.
Table 2. Th Development of Lymph Node CD41 T Cells from 
ICSBP Mutant Mice*
Secretion
Th1 (IL-12 1
anti–IL-4)
Th2 (IL-4 1
anti–IFN-g)
IFN-g IL-4 IFN-g IL-4
ng/ml ng/ml ng/ml ng/ml
Genotype
ICSBP1/1 225 6 10 0 3.4 20 6 4
ICSBP2/2 112 6 56 0.15 3.3 83 6 19
*CD41 T cell purification and cultures were performed as described in
Materials and Methods. Data are representative of four experiments.1539 Giese et al.
ing spleen cells stimulated with ODNs was 11 for the
knockout mice versus 4 for wild-type mice (Fig. 2 B). The
difference in the absolute numbers of IL-12–secreting cells,
as well as the degree of activation, was less dramatic for lymph
node cells. E. coli DNA triggered a threefold increase and
ODNs a six- to sevenfold increase in the quantity of the
IL-12 producers, regardless of genotype. Of interest, the
frequencies of IL-12–secreting cells among unstimulated
spleen and lymph node cells of wild-type mice were sub-
stantially higher than those in cultures from ICSBP-defi-
cient mice, an observation in keeping with the relative lev-
els of IL-12p40 transcripts (Figs. 1 B, 2 B, and 3 B).
Further studies were undertaken to determine whether
the deficit in IL-12 production in ICSBP2/2 mice was in-
dicative of a global change in macrophage and neutrophil
functions or in their responsiveness to LPS, IFN-g, or CD40
crosslinking. It has been reported that thioglycollate-elic-
ited peritoneal macrophages from ICSBP2/2 mice pro-
duced high levels of NO, but were impaired for H2O2
production and anti-Listeria cytotoxicity after in vitro stim-
ulation with LPS and IFN-g (20). In the current study, we
screened selective responses of blood, spleen, bone mar-
row, or peritoneal cavity cells from ICSBP knockouts and
littermate controls to stimulation with IFN-g, IL-4, LPS,
CD40 crosslinking, PMA, and FMLP in vitro, as well as to
thioglycollate in vivo. We found that after appropriate
stimulation, cells from knockout and normal mice were
comparable for (a) production of NO and H2O2, (b) ability
to upregulate MHC class II expression, exhibit a Ca21 in-
flux, and undergo chemotaxis; and (c) transcriptional eleva-
tions of TNF-a, iNOS, IL-6, KC, and MIP-2 (data not
shown).
For cells from either normal or knockout mice, we also
Figure 2. Impaired IL-12 expression in ICSBP2/2 mice. (A) Concen-
tration of IL-12p40 in supernatants obtained from indicated cell popula-
tions after 18–24 h of incubation with 200 U/ml IFN-g in combination
with 100 ng/ml LPS (left) or 1:1,000 diluted preparation of CD40L (right).
Spleen (spl) and bone marrow (bm) cells were plated at 2 3 106/well; nor-
mal peritoneal washout (PC) or thioglycollate-elicited exudate (PEX)
cells were used at 6 3 105/well. In a number of experiments, serial dilu-
tion analysis was performed. Data indicate the mean 6 SEM of IL-12p40
concentration in supernatants from the indicated cell populations as well
as from macrophages (MÆ) enriched by adherence. The results summa-
rize data from two to six experiments with two to three mice in each ex-
periment. (B) ELISpot analysis of the ability of ODN or E. coli DNA to
trigger IL-12p40 secretion by cells from spleen (left) or lymph nodes (right)
of ICSBP2/2 (KO) and ICSBP1/1 (WT) mice. The frequency of IL-12–
producing cells (mean 6 SEM) for three individual mice is shown. (C)
RT-PCR analysis of IL-12p40 RNA expression after 6 h of stimulation
of 107 hematopoietic cells with 100 ng/ml LPS 6 100 U/ml IFN-g. Data
shown are representative of three independent studies. ns, no sample.
Figure 3. Course of L. major infection in ICSBP mutant mice. (A)
Swelling of infected footpads of ICSBP2/2 (KO; n 5 15) and ICSBP1/1
(WT; n 5 10) mice was assessed as described in Material and Methods.
(B) Expression of genes involved in control of the resistance to L. major by
ICSBP2/2 mice. RT-PCR analysis was performed on DLN cells. 7-wk
data represent RNA expression in DLNs obtained on day 49 after infec-
tion. Identical results were obtained for DLNs on day 53. (C) Impairment
of IFN-g but not IL-4 production by DLN cells obtained from infected
ICSBP2/2 mice after restimulation with SLA and Con A in vitro. Data
indicate the mean 6 SEM in supernatants of 8 3 106 cells/ml derived
from 7-wk–infected ICSBP2/2 (KO) and ICSBP1/1 (WT) mice. A sum-
mary of two separate experiments conducted on day 49 and day 53 after
infection is shown.1540 ICSBP Regulation of IL-12 Expression
detected upregulation of IL-12p40 transcription after stim-
ulation in vitro with LPS (Fig. 2 C). Transcript levels were
further enhanced by the addition of IFN-g to the induc-
tion regimen; however, the levels of induction seen with
cells from knockout mice were considerably lower than
those seen with cells from control animals. This suggests
the existence of both ICSBP-dependent and -independent
pathways for IL-12 induction, with the dependent pathway
being more potent. Alternatively, ICSBP may be an im-
portant but nonessential component of IL-12 induction
that amplifies the response when it is present. Together, the
results of RT-PCR analyses and induction studies demon-
strate that ICSBP2/2 mice have greatly reduced steady-state
levels of IL-12 expression and are markedly impaired in their
ability to produce IL-12 in response to a variety of stimuli.
Since IL-12 is a major stimulator of IFN-g synthesis as well as
of NK and CTL activity in vivo and appears to be indispens-
able for generation of protective Th1 immune responses
against intracellular pathogens, we reasoned that T cell–
mediated immunity should be severely altered in ICSBP2/2
mice.
ICSBP-deficient Mice Are Highly Susceptible to Infection with
L. major. ICSBP2/2, ICSBP1/2, and ICSBP1/1 mice were
inoculated in the footpads with 106 viable L. major promas-
tigotes. Enlargement of the infected footpads and dis-
semination of the parasite to the DLNs and internal organs
served as indicators of disease progression. The experiments
were terminated at 53 d after infection when necrotic le-
sions developed in the footpads of ICSBP-deficient mice.
These studies revealed that mice of a normally genetically
resistant background [(B6 3 129) F2], but deficient in ICSBP,
were unable to control the infection. The response to in-
fection of heterozygous mice was similar to that of 2/2
mice (data not shown). At day 6 after infection, the num-
bers of parasites in the footpads of ICSBP2/2 mice were
more than 250-fold higher than those of wild-type mice
(Table 3), although footpad swelling was comparable (Fig.
3 A). Both footpad swelling and parasite numbers then de-
creased for wild-type mice, but progressed inexorably in
the knockout mice, with elevated levels of parasites in the
DLNs and dissemination to the spleen and liver (Table 3).
Histologic studies of infected wild-type mice showed
that the inflamed footpads gradually healed and that there
were no lesions in the spleens or livers (Fig. 4 A). In con-
trast, the footpads of ICSBP2/2 mice exhibited marked swel-
ling with both superficial and deep ulceration, necrosis, and
striking accumulation of extremely heavily parasitized mac-
rophages (@100 parasites/cell). Of interest, the lesions con-
tained few neutrophils or lymphocytes, and signs of
chronic inflammation or formation of granulation tissue
were not observed. Excessive parasite burdens were also
detected in the DLNs (Fig. 4 A), in which isolated foci of
lymphocytes were shouldered to the periphery by sheets of
ballooned, infested macrophages. The DLNs of infected
ICSBP2/2 mice were also significantly enlarged over those
of wild-type animals, with weights of 98 6 19 versus 17 6
3 mg, respectively, at 53 d after infection. The cellularity of
nodes from the knockout mice was increased only 1.5-fold
over that of their wild-type counterparts, however, reflect-
ing the differential contributions of parasitized macro-
phages versus responsive lymphocytes to nodal structure.
Sections from the spleens and livers of infected knockout
mice and controls were strikingly different. Although wild-
type livers appeared intact, the liver parenchyma of the knock-
out mice was modestly infiltrated with macrophages con-
taining large numbers of parasites, and there was noticeable
dilation of the sinusoids and marked accumulation of neu-
trophils and plasma cells in the periportal areas (Fig. 4 A).
The spleens of infected ICSBP2/2 mice showed alterations
in the normal architecture due to sweeping infiltration of
macrophages into the red pulp. The white pulp was small
and nonreactive with periarteriolar lymphoid sheaths con-
taining parasitized macrophages and lacking germinal cen-
ters (Fig. 4 A).
Table 3. Parasite Burdens in Tissues of ICSBP Mutant Mice 
during L. major Infection
Tissues
Days after infection
61 9 4 9 5 3
Foot (log2 titer per mg of tissue)
ICSBP2/2 10 6 1 .15 13 6 18  6  4
(n 5 3) (n 5 3) (n 5 3) (n 5 3)
ICSBP1/1 1 .15 nd† 2 6 2
(n 5 2) (n 5 2) (n 5 3) (n 5 2)
Spleen (log2 titer per 106 of nucleated cells)
ICSBP2/2 –* – 14 6 2 12 6 1
(n 5 5) (n 5 4)
ICSBP1/1 – – nd nd
(n 5 3) (n 5 3)
Draining LN (log2 titer per 106 of nucleated cells)
ICSBP2/2 – – 17 6 1 14 6 1
(n 5 5) (n 5 4)
ICSBP1/1 –– 2   6  11
( n  5  3) (n 5 3)
*–, not done.
†nd, not detectable.
Figure 4. Microscopic examination of tissues from ICSBP mutant mice. (A) Histopathology of infected footpads, liver, spleen, and DLNs of ICSBP2/2
(KO) or ICSBP1/1 (WT) mice injected with L. major on day 49 after infection. Sections were stained with hematoxylin and eosin. The original magnifi-
cation was 4 for liver, spleen, and left DLN panel; 40 for footpads and right DLN panel. Detailed description is given in the text. (B) Photomicrograph of
cytospin preparations of thioglycollate-induced peritoneal washout cells obtained from uninfected ICSBP2/2 (KO) and ICSBP1/1 (WT) mice (Wright’s-
Giemsa stain; original magnification: 100).1541 Giese et al.1542 ICSBP Regulation of IL-12 Expression
The Susceptibility of ICSBP Knockout Mice to L. major Was
Due to IL-12 Deficiency and Failure to Initiate Protective Th1
Responses. The resolution of experimental L. major infec-
tion has been ultimately correlated with IL-12–dependent
development of IFN-g–producing Th1s capable of activat-
ing the leishmanicidal potential of macrophages. To deter-
mine the basis for susceptibility to L. major in ICSBP-defi-
cient mice of otherwise resistant background, we examined
RNA expression of important effector molecules in the
DLNs of infected animals. Infection of 1/1 mice with L.
major induced long-lasting increases in transcription of iNOS,
IFN-g, TNF-a, and IL-12p40 (Fig. 3 B). In contrast, DLNs
of infected ICSBP2/2 mice exhibited undetectable or very
low levels of transcripts for IFN-g and iNOS at any time
after infection, with some mouse-to-mouse variability for
the latter. The TNF-a response of the knockout mice was
similar to that of wild-type mice at 1 and 3 wk after infec-
tion, but was substantially lower at 7 wk. In contrast, low
levels of IL-12p40 were induced at 1 wk after infection and
dropped sharply to barely detectable levels at 7 wk after in-
fection. Thus, in contrast to control mice, ICSBP2/2 mice
failed to develop a curative Th1 immune response.
Several features of IL-12 regulation may be affected in
ICSBP2/2 mice. First, L. major infection caused a gradual
increase in IL-10 expression in DLNs from ICSBP2/2
mice, whereas IL-10 levels remained flat in ICSBP1/1
mice. IL-10 may inhibit IL-12 production by macrophages,
particularly in the absence of IFN-g (43). Second, develop-
mentally staged expression of specific functions by mac-
rophages is a well-known phenomenon (see review in ref-
erence 47), and differences in IL-12p40 inducibility have
been tied to specific stages of monocyte/macrophage dif-
ferentiation/activation (48). Full activation of terminally
differentiated macrophages is marked by increased RNA ex-
pression of c-fms and decreased expression of myeloperoxi-
dase (32). This trend can be seen for transcripts from DLNs
of wild-type mice, whereas expression of myeloperoxidase
persisted in the infected knockout mice and only low levels
of c-fms were seen early after infection (Fig. 3 B). This sug-
gests that myeloid cells were not equally activated or differ-
entiated in ICSBP2/2 and ICSBP1/1 mice. Finally, CD40L
has been shown to be a crucial element in T cell–depen-
dent pathways of macrophage activation, particularly in the
regulation of IL-12 secretion (49–52). Levels of CD40L
transcripts in lymph nodes were similar for mice of both
genotypes before infection and up to 3 wk thereafter, but
were markedly lower for the ICSBP2/2 mice at 7 wk after
infection (Fig. 3 B).
If IL-12 expression is reduced below a critical threshold,
it would be expected that the mice would be able to de-
velop only a Th2 response and would therefore be suscep-
tible to infection. Remarkably, IL-4 transcripts in DLNs of
ICSBP2/2 mice did not differ significantly from those of
wild-type mice at any time after infection, with IL-4 de-
creasing toward the late stages of disease (Fig. 3 B).
To examine the antigen-specific and polyclonal responses
of cells from mice infected for 7 wk, spleen and DLN cells
of wild-type and knockout mice were challenged in vitro
with SLA or Con A, and the supernatants were tested for
expression of IFN-g, IL-4, and NO. After stimulation with
SLA, DLN cells from ICSBP2/2 mice were highly biased
toward expression of IL-4, whereas cells from wild-type
mice were biased toward IFN-g (Fig. 3 C). Cells from mice
of either genotype responded to stimulation with Con A
by producing both IL-4 and IFN-g, indicating that even
after prolonged exposure to infection, T cells retained the
capacity to be activated and to undergo either Th1 or Th2
differentiation, with preference for the latter in ICSBP2/2
mice. Similar results were obtained for spleen cells (data not
shown). Levels of NO in supernatants from DLNs and spleen
cells stimulated with SLA were around the limits of detec-
tion (3 mM) for ICSBP2/2 mice, as compared with 7.4 6
2.9 mM (DLN) and 7.0 6 0.9 (spleen) mM for ICSBP1/1
mice; however, Con A triggered comparable release of NO
by DLNs (5.8 6 0.1 versus 6.5 6 3.3 mM) and spleen cells
(13.1 6 2.6 versus 10.5 6 2.3 mM) from infected knockout
or wild-type mice, respectively. Additional experiments dem-
onstrated that ICSBP2/2 and ICSBP1/1 thioglycollate-
elicited macrophages infected with L. major in vitro and
stimulated with LPS and IFN-g produced similar amounts
of NO (data not shown).
These observations suggest the following sequence of
events leading to progressive infection with L. major in
ICSBP2/2 mice. Upon infection, the parasites quickly in-
fest macrophages and multiply freely in the cytoplasm. This
inefficient parasite containment and a deficiency in the
early IFN-g response may be due either to a yet-unknown
defect in the NK cell compartment or to insufficient IL-12
production by macrophages and dendritic cells. As the dis-
ease advances, IL-12–deficient macrophages stimulated
with suboptimal levels of IFN-g and TNF-a fail to recruit
and activate T cells in parasitized areas, further contributing
to the IFN-g deficiency. This closes the circuit by causing
deficient iNOS expression by macrophages, leading to lim-
ited release of NO, the critical determinant of parasite kill-
ing. Therefore, the problems caused by early deficits in in-
nate immunity, due to the lack of IL-12, are compounded
by the failure to induce Th1 effectors of acquired immu-
nity, resulting in disseminated, progressive disease.
Discussion
Previous studies established that mice deficient in ICSBP
expression exhibit altered hemopoiesis and impaired im-
mune responses to infections with vaccinia virus, lympho-
cytic choriomeningitis virus, and Listeria (20, 21). The fail-
ure of ICSBP2/2 mice to cope with these infections was
ascribed to an IFN-g–related defect in immunity and, in
the case of Listeria, impaired cytotoxicity due to poor pro-
duction of reactive oxygen intermediates in macrophages.
The data presented in this study extend our understand-
ing of ICSBP as a regulator of immune responses to infec-
tions in demonstrating that ICSBP2/2 mice are markedly
deficient in constitutive and induced expression of IL-12.
This defect resulted in the failure of mutant mice infected1543 Giese et al.
with  L. major to mount primary or secondary Th1 re-
sponses and produce IFN-g at high levels.
The defect in the ability of ICSBP2/2 mice to express
IL-12 was relative rather than absolute, with strong stimuli
for phagocytic and dendritic cells being able to induce low
levels of IL-12p40 messenger RNA but little if any protein.
ODN and bacterial DNA, previously shown to activate IL-
12 expression almost exclusively in B cells (26), were the
most efficient inducers of IL-12 production from cells of
both wild-type and knockout mice. Although further work
is required to firmly establish this point, our results suggest
that the defect in IL-12 expression is more profound in the
macrophages and dendritic cells than in the B cells of
ICSBP2/2 mice.
The differential effects of ICSBP deficiency on IL-12 ex-
pression in B cells and macrophages may relate to cell lin-
eage-specific variations in the constitutive and induced levels
of other transcription factors that regulate IL-12 transcrip-
tion. Current studies suggest that ICSBP may participate
directly in the regulation of the IL-12 promoter (Wang, I.-M.,
and K. Ozato, personal communication), possibly as a het-
erodimer with IRF-1 (10). This view is strongly supported
by the findings that the response of IRF-12/2 mice to in-
fection with L. major is remarkably similar to that of
ICSBP2/2 mice (53). In IRF-1–deficient mice, the pro-
duction of IFN-g and IL-12 was greatly reduced, whereas
levels of L. major-specific IgG1 and IgE antibodies were in-
creased. Using different systems, it was concluded that the
failure of Th1 responses to develop in IRF-12/2 mice ei-
ther could, could in part, or could not (53, 54) be ascribed
to Th precursors nonresponsive to IL-12.
Several major differences between IRF-1– and ICSBP–
deficient mice suggest, however, that the phenotype of
ICSBP2/2 mice cannot be understood as the lack of a suit-
able docking partner for IRF-1. These include (a) the dis-
tribution of Ig isotypes in IRF-12/2 mice differs from that
of normal mice only after infection, (b) changes in resis-
tance to infection with L. major are gene dose-dependent in
mice bearing the IRF-1 (53) but not the ICSBP mutation
(data not shown), (c) intact IRF-12/2 mice are highly im-
paired in their ability to produce NO (55), whereas this
function is not affected in ICSBP-deficient macrophages
(20), and (d) the defect in IL-12 expression in IRF-12/2
mice is clearly determined at the transcriptional level as
documented by an absence of IL-12p40 transcripts in cells
stimulated with LPS and IFN-g (54). It should be pointed
out that a model invoking IRF-1/ICSBP heterodimers in
direct regulation of IL-12 expression through ISRE is in-
consistent with analyses of the IL-12p40 promoter by Ma
et al. (56). They reported that deletion of the IRF-1–bind-
ing element had no effect on responsiveness of the pro-
moter in human cells stimulated with LPS and IFN-g,
whereas deletion of an Ets-binding site completely silenced
the promoter. Recently, they described a novel Ets-bind-
ing complex which can activate the human IL-12p40 pro-
moter (57). The ability of ICSBP to complex with IRF-1
and IRF-2 on one hand and with Ets family members on
the other indicates a possible “recruiter–enhancer” func-
tion for ICSBP in regulation of the IL-12p40 promoter.
The structures of murine and human IL-12p40 promoters
were found to differ, and a classic ISRE was not identified
in mice; however, a binding site for PU.1, an Ets family
member, was found in close proximity to a NF-kB half site
(58), making a “cooperative” hypothesis for the role of
ICSBP in regulation of IL-12p40 expression more attractive.
It is also conceivable that other factors known to inhibit
IL-12 production, IL-4, IL-6, IL-10, TGF-b, PGE2, or type I
IFN, may contribute to the low IL-12 phenotype of ICSBP2/2
mice (41, 43, 59). For example, recent studies of dendritic
cells deficient in IL-12 expression as the result of treatment
with PGE2 promoted the development of Th2s (60).
Perhaps the clearest results to come from this study are
the repeated demonstrations that ICSBP2/2 mice are func-
tionally Th2 animals. This includes the following observa-
tions: (a) serum Ig isotypes in uninfected ICSBP-deficient
mice were remarkable for high levels of IgG1 and IgE and
lower than normal levels of IgG2a, (b) the ratio of IgG2a/
IgG1 flu-specific antibodies in sera of ICSBP1/1 mice was
essentially reversed in flu-infected ICSBP2/2 mice, (c) (B6 3
129) F2 mice, normally resistant to L. major, were suscep-
tible if homozygous for the ICSBP mutation, and (d) the
secondary antigen-specific responses of L. major-infected
ICSBP2/2 mice were characterized by elevated production
of IL-4 and the absence of IFN-g. Since purified CD41 T
cells from ICSBP2/2 mice could be induced to differenti-
ate into Th1s in vitro, and nonspecific activation of cells
from L. major–infected ICSBP2/2 mice with Con A in-
duced IFN-g secretion, the defect in vivo can be ascribed
to an environment deficient in stimuli that promote Th1
differentiation. This result underscores the significance of
IL-12 for development of antigen-specific Th1 responses in
vivo.
The mechanisms mediating resistance to infection with
L. major have become increasingly clear over the last few
years (61–67). In resistant mice, the curative response is as-
sociated with early production of IL-12 and is crucially de-
pendent on parasite containment mediated by activated NK
cells and IFN-g. Presentation of parasite antigen by infected
macrophages and dendritic cells results in the antigen-specific
priming and differentiation of chemokine-recruited T cells
into Th1 effectors locally and in the DLNs. Induction of
iNOS and production of NO affect parasite killing within
macrophages. This pattern of resistance was found to be al-
tered in ICSBP2/2 mice at many steps along this path, be-
ginning with low-level induction of IL-12. Subsequently,
we documented impaired induction of IFN-g, iNOS, and
NO, with the end result being progressive, fulminant leish-
maniasis.
IL-12 deficiency and its downstream repercussions, while
likely the overriding influence in the failed response of
ICSBP2/2 mice to L. major, may not be the only features
contributing to the severity of the infection. Although
macrophages infiltrated the inoculated foot rapidly and in
high numbers, the lesions were notably deficient in infil-
trating lymphocytes, similar to the case of anergic cutane-
ous leishmaniasis in humans (68). The paucity of respond-1544 ICSBP Regulation of IL-12 Expression
ing lymphocytes may be part of the reason for the limited
cytokine responses by T cells as determined by RT-PCR.
With disease advancement, the masses of infested macro-
phages aggressively displaced lymphocyte populations,
drastically changing the architecture of involved tissues and
organs.
It is also possible that responding macrophages are not at
the same stage of maturity or activation in wild-type and
knockout mice. Developmentally distinct macrophages are
known to differ in their functional phenotypes (see reviews in
references 47, 69). The findings of differential use of ISRE-
positive promoters by the maturationally distinct WEHI-3
and RAW 264.7 cell lines (70, 71) and the dependency of
the expression of the ISRE-carrying gene, crg-2 (IP-10),
on the state of macrophage inflammatory activity in mice
(72, 73), indicate the possibility of direct involvement of
IRF family members in developmentally staged expression
of macrophage functions. During our studies, we found
that elicited peritoneal macrophages in uninfected mice of
the two genotypes appeared to be equally phagocytic while
differing in morphology (Fig. 4 B). In addition, macro-
phages in DLNs of infected mice differed in their expres-
sion of markers associated with maturational states. These
variations between macrophages of normal and mutant mice
may be associated with developmentally determined differ-
ences in IL-12 expression (41, 48) as well as with cytotoxic
and antigen-presenting functions.
Since ICSBP is expressed in activated but not resting T cells
(6), some of the abnormalities exhibited by T cells of in-
fected ICSBP2/2 mice may be attributable to altered ex-
pression of genes containing ISREs. We found that two ISRE
elements are present in the promoter of the CD40L gene at
positions 2361 to 2348 and 2141 to 2125 (74). Expres-
sion of CD40L transcripts was well maintained in unin-
fected, highly purified CD41 T cells from ICSBP2/2 mice
(data not shown); however, transcripts for CD40L dropped
markedly during the later stages of infection in knockout
but not in wild-type mice.
Although molecular mechanisms remain to be defined in
detail, it is clear from this work that defective expression of
IL-12 and resulting enhanced susceptibility to certain infec-
tions are hallmarks of ICSBP deficiency.
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